Parenteral administration of PB is useful for administering maintenance therapy in hospitalized patients that are unable to take oral medication.
Patients who received CHOP chemotherapy for induction treatment have an initially improved survival when administered maintenance rituximab following CHOP chemotherapy compared to patients who received CHOP chemotherapy only.
Some clinicians advocate delaying chemotherapy after first-line treatment instead of administering maintenance therapy immediately post-induction for some patients, particularly those with few disease symptoms, better performance status (PS), or those who may be more likely to experience the risks of chemotherapy as opposed to the benefits [ 4, 22– 25].
Most closers struggle to gain command of their secondary pitches because they throw relatively few innings and cannot administer proper maintenance.
The PCA pump was set to administer a maintenance dose of 0.02 mL/kg (0.02 mg/kg morphine or 0.05 μg/kg sufentanil) with a lockout interval of 8 minutes in all patients.
When administered as maintenance therapy in the setting of platinum-sensitive relapsed HGSOC, PARPi prolong progression-free survival (PFS), with some patients deriving durable benefit for more than 3 years2,3,4,5,6.
The administered vancomycin maintenance dose compared well with institutional and national guidelines (16.3 ± 2.4 mg/kg).
Subsequently, all 64 patients were administered a maintenance dose of 75 mg clopidogrel per day.
Intravitreal pegaptanib 0.3 mg was administered as maintenance every 6 weeks for 48 weeks with follow-up to week 54.
Bevacizumab combined with chemotherapy not only affected tumour progression, but when administered as maintenance regimen significantly prolonged survival, reducing ascites, and tumour dissemination.
The safety of single-agent pemetrexed administered as maintenance [ 32, 33] and second-line treatment of advanced NSCLC [ 31] has also been established.
